Moderna has made its first-ever acquisition with the $85m purchase of OriCiro Genomics, a Japanese bioventure with DNA synthesis and amplification technology. The deal is expected to contribute to Moderna’s capabilities in both manufacturing and R&D.
High-profile mRNA specialist Moderna, Inc. has put some of its financial windfall from the COVID-19 pandemic to use by entering into a definitive agreement to acquire OriCiro Genomics, a Japanese bioventure based in Tokyo with cell-free DNA synthesis and amplification technologies, for $85m.
The deal marks the first acquisition by the US-based firm, which sprung to global prominence during the pandemic for its...
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
